Eli Lilly agreed to a $1.2 billion partnership with Suzhou Sanegene Bio to access tissue‑selective RNAi delivery platforms for metabolic disease programs, including obesity. The transaction gives Lilly options to develop RNA interference therapeutics with targeted biodistribution, reflecting Big Pharma’s renewed appetite for RNAi modalities beyond siRNA liver programs. The deal aligns with Lilly’s broader metabolic pipeline investments and signals accelerating commercialization interest in non‑liver RNAi delivery.